We believe that the rare community will unlock the next generation of medicine

Who are we, and why are we doing this? We get that question a lot. When Flawnson and Albert founded Comend in 2023, we had a simple motivation: to make translational research — early-stage work with real-world impact — accessible to everyone, not just experts.

Drawing from our experiences in drug discovery and healthcare, we saw firsthand the critical benefits of involving patients and their loved ones directly in the development of new solutions. Frankly, it still surprises us that this isn’t common practice. We firmly believed and still do, that while good science doesn’t come from everywhere, it can come from anywhere.